High doses of recombinant α‐interferon or γ‐interferon for chronic hepatitis C: A randomized, controlled trial
Federico Sáez‐royuela, Juan Carlos Porres, Alberto Moreno, Inmaculada Castillo, Gracia Martinez, Fernando Galiana, Vicente Carreño – 1 February 1991 – Chronic hepatitis C is often a progressive liver disease for which there is no satisfactory treatment. We studied the efficacy of recombinant α‐interferon or γ‐interferon in the treatment of this disease in comparison with a control group. Thirty patients were randomly assigned to three groups. Ten patients received 7.5 MU α‐interferon/m2 body surface three times weekly for 3 mo, then 5 MU/m2 for 3 mo and 2.5 MU/m2 for 6 mo.